Partnership expands spectrum of Secarna's capabilities for the development of targeted ASOs beyond antibodies and sugar molecules New platform capabilities extend the reach of Secarna's antisense
EQS-News: Secarna Pharmaceuticals GmbH & Co. KG / Key word(s): AgreementSecarna Pharmaceuticals and Orbit Discovery enter collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide therapeutics 28.05.2024 / 13:00 CET/CESTThe issuer is solely responsible for the content of this announ.
EQS-News: Secarna Pharmaceuticals GmbH & Co KG: Secarna Pharmaceuticals presents data at SITC demonstrating the potential of antisense oligonucleotides in targeting NRP1 finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Secarna Pharmaceuticals Presents Data at SITC Demonstrating the Potential of Antisense Oligonucleotides in Targeting NRP1 nashvilleherald.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nashvilleherald.com Daily Mail and Mail on Sunday newspapers.